Nordic Nanovector ASA: Third Quarter 2016 Results Presentation and Webcast
Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development and commercialisation of novel targeted
therapeutics in haematology and oncology, will announce its third quarter 2016 results on Wednesday, 23 November 2016.
A presentation by Nordic Nanovector’s senior management team will take place at 8:30 am CET at:
Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: BJØRVIKA
The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investor Relations/Webcast.
The results report and the presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Quarterly Reports/2016 from
7:00 am CET the same day.
About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in
haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin
Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing
market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to
as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety
profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing
Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector
intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while
exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to
treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
Nordic Nanovector
IR:
Tone Kvåle, +47 91 51 95 76
Chief Financial Officer
ir@nordicnanovector.com
or
Media:
Mark Swallow / David Dible (Citigate Dewe Rogerson), +44 207 282 2948 / +44 207 282 2949
mark.swallow@citigatedr.co.uk / david.dible@citigatedr.co.uk
View source version on businesswire.com: http://www.businesswire.com/news/home/20161115006894/en/